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1. Introduction 
In this era of personalised medicine, the focus of oncology drug development is shifting 
from classic chemotherapeutic drugs to rationally designed molecularly targeted agents 
(MTAs). This development has been accelerated by improved understanding of the key 
features of human tumour biology which have emerged over the last decade. A seminal 
paper by Hanahan and Weinberg (2000) proposed six vital elements for tumour formation, 
survival and progression. The six ‘Hallmarks of Cancer’ were sustained proliferative 
signalling, evasion of growth suppressors, resistance to cell death, replicative immortality, 
angiogenesis and activation of invasion and metastasis. Hanahan and Weinberg updated 
their findings in 2011 with further evidence describing the complexity of these hallmarks 
and the addition of further hallmarks, including modification of energy metabolism to fuel 
cell growth and evasion of immunosurveillance. The tumour micro-environment is also a 
critical factor in the regulation of tumour growth and progression, with multiple stromal cell 
types creating a succession of supportive tumour micro-environments enabling invasion of 
normal tissue and subsequent metastasis.  
Recent successes have utilised these advances in understanding to create a strong biologic 
rationale for drug development, primarily focusing on targets of a single ‘Hallmark’.  
However, a number of challenges remain, not only in understanding the complex molecular 
pathways and networks, their interaction and mechanisms of resistance, but also in the drug 
development process through early incorporation of biomarkers to create rational drug 
development strategies. Challenges also lie in defining robust criteria to appropriately select 
patients for novel therapies. Effective trial design with integration of patient enrichment 
strategies is paramount to streamline drug development and deliver timely information to 
guide progress of drugs along the pipeline. The application of new technologies and novel 
strategies that address these problems will be discussed in detail in this chapter.  
2. From hypothesis to proof of concept 
Historically, the emphasis for drug development has focused on evidence-based medicine in 
large trials of unselected patient populations, with the benchmark endpoint for new drugs 
being overall survival or other intermediate endpoints. This ‘one size fits all’ paradigm did 
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not always take into account intra- and interpatient tumour heterogeneity commonly 
leading to large scale failure rates of multinational phase-III trials.  
Incorporating measures of pathway activity and tumour efficacy into early phase trials may 
help avoid failure in later phases of drug development. Early validation of 
pharmacodynamic assays to measure target blockade and assess optimal dose range and 
dosing schedule is essential. Establishing ‘proof-of-concept’ can then correlate anti-tumour 
activity in a selected patient population with validated predictive and intermediate 
endpoint biomarkers (De Bono & Ashworth., 2010). 
For example, in patients with non-small cell lung cancer (NSCLC), correlation of epidermal 
growth factor receptor (EGFR) mutations with response to the EGFR inhibitors, gefitinib or 
erlotinib, occurred only after a number of negative trials. Although phase-II data in the 
second-line setting in patients with NSCLC was encouraging, when taken to a phase-III trial 
in an unselected group of patients with refractory disease, gefitinib failed to show a benefit 
in either overall survival or time-to-treatment failure when compared to placebo (Thatcher 
et al., 2005). In this context, it was only that retrospective analyses could help identify a sub-
population benefiting from treatment including being a female, never-smoker and of Asian 
origin. Similarly, erlotinib demonstrated progression-free and overall survival benefits both 
in the second-line setting and as maintenance therapy in patients with stable disease after 
first-line chemotherapy (Cappuzzo et al., 2010; Shepherd et al., 2005). However, the 
incremental benefits in these unselected patient populations were small, measured in weeks 
for progression-free survival and 1-2 months for overall survival. Ultimately it was the 
selection of patients based on EGFR mutation status that demonstrated a marked 
improvement in response rates and survival in phase-III trials comparing chemotherapy and 
gefitinib (Fukuoka et al., 2011), as well as chemotherapy and erlotinib in the first-line setting 
(Rosell et al., 2011).  
We have witnessed similar studies in patients with advanced colorectal cancer (ACRC) 
treated with the monoclonal antibody cetuximab. Initially, treatment with cetuximab was 
conducted in patients with EGFR over-expression, assessed by immunohistochemistry 
(IHC) on formalin-fixed paraffin-embedded (FFPE) tumour specimens (Cunningham et al., 
2004). It was only later that the importance of Kirsten rat sarcoma-2 virus oncogene (KRAS) 
mutation was demonstrated; and this, in combination with an increased understanding of 
the complex EGFR downstream signalling cascade were the first steps in identifying a 
predictive biomarker for EGFR directed therapies in patients with ACRC. Several studies 
identified that patients with KRAS mutation did not respond to EGFR directed therapies, 
whereas patients who had wildtype (wt) KRAS tumours had response rates of over 50% 
(Lievre et al., 2006; Karapetis et al., 2008). More recently, it has been demonstrated that in 
fact, not all KRAS mutations are created equal. Although the presence of the majority of 
KRAS mutations precludes response to the EGFR inhibitors in ACRC, other KRAS 
mutations, particularly in codon 13, may predict a response similar to that demonstrated in 
wt KRAS tumours (De Roock et al., 2010). 
These are just a few examples that demonstrate how the improved understanding of tumour 
biology supports a hypothesis-driven approach to the discovery of compounds to 
potentially generate more selective inhibition of key signalling proteins, pathways and 
networks. In this context, one of the most challenging tasks is the identification of the right 
target and more importantly whether this target is ‘druggable’. For example, although we 
know that RAS mutations are an early component of tumorigenesis and are identified in 
approximately 30% of human cancers, attempts to target RAS have been unsuccessful to 
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date as complex molecular structures constrain binding to the active site or pocket (Gysin et 
al., 2011). In contrast, selective inhibition of the v-raf murine sarcoma viral oncogene 
homologue B1 (BRAF) in patients with BRAF V600 mutant melanoma is associated with a 
dramatic improvement in response rates and survival. The strong biologic rationale of this 
approach was established through identification of the importance of the mitogen-activated 
protein kinase (MAPK) pathway in this disease and will be discussed at a later point in this 
chapter.  
3. Biomarker development  
Predictive and prognostic biomarkers are increasingly important in tailoring treatment 
decisions for individual patients. These markers are objectively measured to evaluate 
pathological processes or pharmacological responses to a therapeutic intervention, and can 
be any kind of molecule, substance, or genetic marker which is traceable (Atkinson et al., 
2001). Predictive biomarkers provide information on response to a treatment, whereas 
prognostic biomarkers give information about outcome independent of the treatment effect. 
Historically, biomarkers have often been developed in retrospective analyses and were only 
in some cases prospectively applied. The retrospective approach was often criticised for 
being slow and difficult in practice, as well as raising concerns regarding heterogenous 
sample collection and validity. There are increasing efforts to incorporate new biomarker 
strategies into the earliest stages of clinical trial design, whether these are mutational 
analyses, clinical, or imaging measures, so that information can be gathered early and 
continually revisited during and after trial completion to inform the clinical development 
process.  
As witnessed with a number of targeted agents, such as trastuzumab in human epidermal 
growth factor receptor-2 (HER2) positive breast cancer, the prospective analysis of HER2 as 
a predictive biomarker in clinical trials resulted in higher response rates and increased 
survival in this selected patient population, both in the metastatic and adjuvant setting 
(Slamon et al., 2001; Romond et al., 2005). This selective approach not only led to better 
outcomes for this subgroup, but ultimately to shorter and streamlined regulatory approval 
timelines. The use of trastuzumab in an unselected breast cancer population would 
undoubtedly have masked its true efficacy and potentially curtailed its development. 
Importantly this selective biomarker approach became a good example of what challenges 
researchers are facing when developing accurate, functional and standardised biomarker 
assays.  
HER2 gene amplification was first observed to be a potential biomarker in breast cancer 
when its presence in 25% of axillary lymph-node positive breast cancers was correlated with 
worse prognosis (Slamon et al., 1987). Additional studies confirmed that HER2 protein over-
expression was also a poor prognostic marker in breast cancer, correlating with decreased 
relapse-free and overall survival (Ravdin et al., 1995). The trastuzumab clinical trials were 
initially designed using HER2 over-expression measured by IHC with a centralised sponsor 
developed assay, which was particularly important as there was no standardised assay at 
that time. As the testing of HER2 was expanded from central to local laboratories, with 
incorporation of fluorescence in-situ hybridisation (FISH) in addition to IHC, there were 
concerns about the correlation and regulation of such assays. 
Although the results of the five adjuvant trastuzumab trials in HER2 positive early stage 
breast cancer clearly showed a significant clinical benefit in both progression-free and 
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overall survival, the testing algorithms for HER2 were not consistent across these trials. 
HER2 testing included either IHC supported by FISH testing for intermediate IHC result 
(IHC2+) or reliance on FISH testing alone to assess gene amplification ratios. Concern was 
generated at the lack of accuracy and validation of HER2 testing in some instances as several 
assays were in use, including both validated assays, but also so called “home brew” assays 
developed in local pathology laboratories. Sub-studies from two of the adjuvant trials 
demonstrated that approximately 20% of HER2 assays performed at the primary treatment 
site were incorrect compared to re-evaluation in a high volume, central laboratory (Paik et 
al., 2002; Roche et al., 2002). Furthermore, the sensitivity of IHC itself was of concern. For 
example, one study demonstrated that commercially available US Food and Drug 
Administration (FDA) approved IHC methods were significantly less accurate than FISH at 
correctly characterising tumours with known HER2 status. Depending on the IHC method 
and use of HER2 antibody, correlation with FISH positivity ranged between 67-83%, with 
greater susceptibility to inter-observer variation (Bartlett et al., 2001).  
Clearly in the case of IHC testing, several contributing factors may further impact on 
sensitivity and specificity including initial sample processing, time to and type of fixation, 
analytic variables of assay validation, equipment calibration, use of standardised laboratory 
procedures, training of staff, test reagents, use of standardised control materials and use of 
automated laboratory methods.  
Slamon et al. (1989) demonstrated that a proportion of breast cancers known to have gene 
amplification and over-expression of HER2, in fact lose membrane staining after paraffin 
embedding and are negative on IHC assessment. Loss of antigenicity resulting in a potential 
false negative IHC can be affected by poor standardisation of fixative methods.  
To overcome this lack of concordance in HER2 testing, which can so markedly impact on 
patients’ prognosis and survival, an American Society of Clinical Oncology (ASCO) panel 
developed guidelines to improve the accuracy of HER2 testing (Wolff et al., 2007). These 
recommendations covered over 30 aspects of testing and requirements including the HER2 
testing algorithm, optimal FISH and IHC testing and interpretation, tissue handling, internal 
validation and quality assurance procedures, optimal external proficiency, laboratory 
accreditation and regulatory requirements, statistical requirements for assay validation and 
international external quality assessment initiatives. Despite these guidelines, there were 
concerns that IHC assessment still lacked sufficient sensitivity to be used alone to decide on 
HER2 status (Carlson., 2008) though this remains the standard initial assessment in most 
laboratories. 
In 2010, the addition of trastuzumab to first-line chemotherapy in HER2 positive advanced 
gastric cancer demonstrated a survival benefit (Bang et al., 2010). Similar to breast cancer, 
approximately 20-30% of gastric and gastro-oesophageal junction (GOJ) cancers show HER2 
over-expression, but the testing criteria in gastric specimens differs significantly (Albarello 
et al., 2011). This is related to the increased frequency of heterogeneity of HER2 positivity in 
gastric cancer compared with breast cancer, as well as variations in membrane staining and 
the number of stained cells necessary to diagnose a positive case. In addition there is also 
less stringent correlation between HER2 amplification and protein over-expression with 
more than 20% of cases carrying HER2 amplification, often of low level, without HER2 
expression. Clinically in this group of patients, there is no apparent benefit from adding 
trastuzumab to chemotherapy (Bang et al., 2010). Similarly, Hofmann et al. (2008a) 
demonstrated concordance between FISH and IHC of 93%, with 7% of specimens 
demonstrating FISH positivity with negative or equivocal IHC staining.  
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Discordant findings have also been demonstrated with HER2 testing on surgical specimens 
compared to biopsy alone, with more than 10% of cases showing discrepant results (Yano et 
al., 2006). As a result, if only gastric or GOJ cancer biopsy samples are available for HER2 
testing, current guidelines recommend sampling of at least 6 different areas of the tumour 
for HER2 analysis. New IHC scoring criteria have also been developed for gastric and GOJ 
cancers and were validated by Hofmann et al. (2008b), further demonstrating that the 
analysis of HER2 based on the breast cancer guidelines may lead to false negative reporting 
in gastric cancer specimens.  
This example demonstrates that although an assay may have progressed through thorough 
validation and review processes in one cancer sub-type, its use cannot be assumed for other 
malignancies and re-validation needs to be incorporated into early phase trials, particularly 
when the drug is readily available and may otherwise rapidly proceed to clinical practice. 
Furthermore, when several IHC assays exist, it is of the utmost importance that laboratories 
validate their internal IHC and FISH procedures according to international guidelines. 
In this context it is paramount that biomarker development is orchestrated collaboratively in 
large multi-institutional networks. The integration of biomarkers early in drug development 
and correlation with clinical observations can generate early signals of unexpected efficacy 
or resistance that can then be used to change the direction of development of a particular 
drug and enhance outcomes. 
Furthermore new health information technologies (HIT) are a pivotal part of biomarker 
development and need to be linked into routine practice to support the large-scale 
information of tumour biology and clinical data. The use of HIT will also support the 
integration of a variety of data sets including gene expression profiles, metabolic, 
immunohistochemical profiles and clinical outcome data. The development of next 
generation sequencing, functional genomic screening and transcriptional analysis offers 
detailed insight not only into DNA sequence, but also into mRNA profiles, protein structure 
and metabolic pathways. The enormity of the information that is available needs parallel 
information technologies to interpret and link these findings to their regulated networks. 
The ultimate application of these technologies involves the modelling of interacting 
pathways to make phenotypic predictions and develop complete system models to advance 
personalised drug development. The incorporation of molecular biology and information 
technology can thus maximise the interpretation, application and targeting of these complex 
oncological systems. In this context, bioinformatics has evolved to combine sequence 
matching and pattern discovery with modelling of dynamic biological systems to enhance 
the drug discovery process. 
4. Developments of new rationally designed targeted therapies 
Several recent phase-I trials of molecularly targeted agents have demonstrated remarkable 
progress when patients were selected based on their molecular profile and subsequently 
treated with an agent directed against this specific target.  
The shift from ‘one size fits all’ to molecularly defined subpopulations has been particularly 
successful in the treatment of patients with advanced BRAF mutant cutaneous melanoma. 
Two pivotal phase-I trials, showed encouraging response rates and improved survival rates 
with the selective BRAF inhibitors, vemurafenib (PLX4032) and GSK 2118436, in a disease 
notoriously resistant to standard chemotherapies. Another trial in patients with NSCLC 
who were carriers of the EML4-ALK fusion protein showed remarkable response rates with 
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the new ALK inhibitor, crizotinib. The successful development of such agents is of course 
complex but can be simplistically considered as having three key components: the right 
target (strong biologic rationale, druggable), the right drug (selective, right formulation, 
tolerable side-effect profile) and the right biomarker (reproducible, validated) (Figure 1). 
This paradigm can be further evidenced by the success of imatinib and CAL-101 in 
haematological malignancies and reflects the limitations that have impacted on the use of 
other agents, such as sorafenib in melanoma or bevacizumab in breast and other 
malignancies.  
 
 
Fig. 1. Key Components of Oncology Drug Development 
Sorafenib is an oral multikinase inhibitor of vascular endothelial growth factor receptor 
(VEGFR), platelet derived growth factor receptor (PDGFR)-β and Raf-1 (Wilhelm et al., 
2006). Although it was initially developed as a RAF inhibitor, sorafenib showed only 
moderate IC50s for all three RAF isoforms and also had inhibitory effects on several other 
receptor tyrosine kinases including VEGFR2, VEGFR3, PDGFRβ, cKIT and FLT3. Sorafenib 
has demonstrated significant improvements both in clinical benefit rate and survival in renal 
cell carcinoma (RCC) and hepatocellular carcinoma (HCC) (Escudier et al., 2005; Llovet et 
al., 2008). Correlative markers were incorporated into these trials including phosphorylated 
ERK (pERK) immunostaining and soluble c-KIT, VEGFR2, VEGFR3 and VEGF levels. As yet 
however, there is no validated biomarker to predict the target patient population. 
Despite a good biologic rationale to support its use in melanoma and promising early phase 
trials, sorafenib failed to show a clinical benefit in phase II-III trials (Eisen et al., 2006; 
Hauschild et al., 2009). Unlike the early phase trials for the selective BRAF inhibitors, 
patients were not selected for BRAF mutations, one of the key drivers in cutaneous 
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melanoma, nor were the pharmacodynamic markers from the early phase trials translated 
into the design of the phase-III trials. The failure of this drug development programme in 
melanoma could have been mitigated if phase-II data had been critically reviewed and early 
‘go or no-go’ decisions had been incorporated in the decision making process for the phase-III 
trials.  
Similarly, the development of bevacizumab as a drug targeting the ‘angiogenic switch’ and 
tumour-associated neo-vasculature met with much anticipation (Hanahan & Folkman, 
1996). Bevacizumab is a humanised monoclonal antibody targeting VEGF-A and its binding 
to VEGFR2. There was early pre-clinical evidence that it not only inhibited the formation of 
new blood vessels, but also caused regression of existing micro-vessels and stabilised the 
mature vasculature to improve drug delivery. Significant clinical benefit Has been 
demonstrated with bevacizumab in combination with chemotherapy in advanced colorectal 
cancer but despite promising data regarding potential clinical, biochemical and radiological 
parameters, a predictive biomarker remains elusive (Hurwitz et al., 2004; Jubb & Harris, 
2010). Although bevacizumab is now approved in several disease entities, the broad use in 
many tumour types remains controversial, bearing in mind its associated cost and toxicity. 
In this context, the lack of proven and validated biomarkers to predict the patient 
population most likely to benefit is often criticised and in part may have contributed to the 
withdrawal by the FDA of its approval in metastatic breast cancer.  
On the contrary, the development of selective BRAF inhibitors for BRAF V600 mutation 
positive advanced cutaneous melanoma commenced with a strong biologic rationale and its 
success was facilitated by the validation of an associated predictive biomarker (Figure 2). 
Aberrant activation of the MAPK pathway has been demonstrated in over 80% of primary 
melanomas, due to abnormalities at various levels’ along the RAS-RAF-MEK-ERK pathway 
with subsequent acceleration of cell growth, proliferation and differentiation (Platz et al., 
2008). BRAF mutations are among the most studied, occurring in 36-59% of primary 
melanomas (Houben et al., 2004; Jakob et al., 2011; Long et al., 2011) and 42-66% of 
metastatic melanomas and have been characterised as oncogenic mutations (Davies et al., 
2002; Karasarides et al., 2004). Early phase trials with the selective BRAF inhibitors, 
vemurafenib (PLX4032) and GSK 2118436, have demonstrated response rates far higher than 
standard chemotherapy with impressive improvements in survival (Chapman et al., 2011; 
Flaherty et al., 2010; Kefford et al., 2010; Ribas et al., 2011.). Thus, the identification of ‘the 
right target’, the BRAF mutation, lent itself to the development of ‘the right drug’, the selective 
BRAF inhibitors, whose efficacy could be predicted by ‘the right biomarker’, presence of a 
BRAF mutation. 
Activating mutations or translocations of the anaplastic lymphoma kinase gene (ALK) have 
been identified in several types of cancer, with the EML4-ALK fusion gene evident in 2-7% 
of all NSCLC. EML4-ALK is an aberrant fusion gene that encodes a cytoplasmic chimeric 
protein with constitutive kinase activity. It is more prevalent in patients who are never or 
light smokers and in patients with adenocarcinoma histology. Crizotinib is a selective 
inhibitor of the ALK and MET tyrosine kinases and has shown unprecedented response 
rates and clinical benefit in a phase-I trial of heavily pretreated patients with advanced 
NSCLC harbouring ALK rearrangement (Kwak et al., 2010). The study incorporated 
molecular analysis of tumour samples with prospective tumour genotyping, including 
analysis via FISH, IHC and reverse-transcriptase-polymerase-chain-reaction (RT-PCR). FISH 
positivity for ALK rearrangement strongly correlated with aberrant expression of the ALK 
protein on IHC and many patients, though not all, also had positive results for EML4-ALK 
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on the RT-PCR assay. The use of prospective tumour genotyping not only potentiated the 
development of diagnostic approaches for these patients but has also streamlined rapid 
drug development for crizotinib. Remarkably, there were only three years between target 
identification, initiation of the phase-I trial and enrolment on the phase-III registration trial 
and stands in contrast to more than ten years from the initial unsuccessful trials of EGFR 
inhibitors in non-genotyped unselected patients to the phase–III trials that demonstrated 
benefit of EGFR inhibitors in EGFR-mutant tumours (Kwak et al., 2010). Again, there is 
strong supporting evidence for ‘the right target’ and ‘the right drug’ in this setting, whilst 
development of ‘the right biomarker’ has been incorporated into the phase-I trials to assist in 
overcoming the many complexities inherent with new assay validation. 
 
1. Development of a strong biologic rationale 
Mutations along the MAPK pathway present in up to 80% of metastatic melanomas 
In vitro evidence with vemurafenib (PLX4032) and GSK 2118436 of selective inhibition of 
BRAF V600E and impaired tumour growth in mouse models 
2. Biomarkers for early phase trials 
Prognostic Biomarker: BRAF aberrations 
Predictive Biomarker: BRAF V600E aberrations (and V600K with GSK118436) 
Pharmacodynamic Biomarkers: pMEK and pERK 
3. Confirmation of a clinical response 
Phase 1/2 trials (vemurafenib): RR 50-80%; PFS >7m 
Phase 1/2 trials (GSK 2118436): RR 60%; PFS 8.3m 
Phase 3 trial (vemurafenib vs dacarbazine):  RR 48% v 5%; PFS 5.3m v 1.6m  
    OS at 6m 84% v 64% 
4. Dissecting the Mechanisms of Resistance 
Longitudinal biopsies pre-treatment, on treatment and on progression 
On-target effect demonstrated by suppression of pMEK and pERK, and decreased staining 
of proliferative markers on IHC (cyclin D1 and Ki67) 
Resistance possible through alternate signalling in MAPK pathway or via bypass pathway 
signalling 
Vemurafenib  
Some tumours demonstrate increased pMEK/pERK on progression with reactivation of 
MAPK pathway 
Evidence of NRAS and MEK mutations which mediate signalling via the MAPK pathway  
Evidence of PTEN loss and increase pAkt demonstrates activation of PI3K-AKT-mTOR 
pathway 
GSK 2118436  
Abnormal PTEN associated with shorter PFS and loss of inhibition of the PI3K-AKT 
pathway 
CDKN2A and KIT deletion associated with shorter PFS 
MAPK: mitogen-activated protein kinase; IHC: immunohistochemistry;  
BRAF: v-raf murine sarcoma viral oncogene homologue B1; 
pMEK: phosphorylated MEK; pERK: phosphorylated ERK; pAKT: phosphorylated AKT; RR: response 
rate; PFS: progression-free survival, OS: overall survival;  
PI3K: phosphatidylinositol 3-kinase; mTOR: mammalian target of rapamycin  
Fig. 2. Selective BRAF Inhibitors for BRAF mutant Metastatic Melanoma 
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In haematological malignancies, the development of the phosphatidylinositol 3-kinase 
(PI3K) inhibitor, CAL-101, has shown encouraging results in advanced non-hodgkins 
lymphoma (NHL), mantle cell lymphoma and chronic lymphocytic leukaemia (CLL) 
(Herman et al., 2010). CAL-101 is a selective inhibitor of the PI3K p110 δ isoform that is 
primarily expressed on cells of haematopoietic origin and has a key role in B cell maturation 
and function. Through inhibition of PI3K signalling, CAL-101 can induce apoptosis of 
primary CLL and acute myelogenous leukaemia (AML) cells and a range of other leukaemia 
and lymphoma cell lines (Lannutti et al., 2010). In phase–I studies, CAL-101 has 
demonstrated durable clinical responses in a number of haematological malignancies, 
including NHL (Flinn et al., 2009). Reduction in phosphorylated AKT (pAKT) as a marker of 
PI3K activation provides ‘proof-of-mechanism’ for this agent and later phase trials are 
underway in B cell malignancies with markers along the PI3Kδ pathway acting as predictive 
biomarkers. 
These recent ‘proof-of-concept’ studies were the first of their kind where molecular profiles 
were used for selection of ‘new in class’ compounds and demonstrate that when patients are 
appropriately selected, convincing benefit can be realised in the earliest of trials, setting the 
stage for rapid drug approval. This phase-I experience has convinced investigators that 
tumour profiling and patient selection will become a routine part of cancer drug 
development. 
5. Challenges in drug development  
5.1 Mechanisms of resistance 
Despite the advances in parallel drug and biomarker development in early clinical trials, one 
of the major challenges remaining is the understanding of mechanisms that cause primary 
and acquired or secondary resistance. Primary resistance is characterised by lack of efficacy 
of an agent from treatment initiation, whereas acquired resistance develops after an initial 
response of some degree over a period of time. 
As evidenced by all currently approved molecularly targeted agents, initial treatment may 
yield response rates far higher than standard chemotherapy with impressive disease control, 
but inevitably resistance and tumour progression develops. Importantly, understanding the 
mechanisms of resistance can lead to rationally designed drug combinations incorporating 
targeted agents, antibodies, or cytotoxics. This approach should include continuous analysis 
of tumour material via biopsies on disease progression or surrogate markers such as 
circulating tumour cells (CTCs) or circulating free DNA (cfDNA). In this context, cancer 
treatment could follow strategies as witnessed by the treatment of tuberculosis with 
quadruple combination regimens or human immunodeficiency virus (HIV) with highly 
active antiretroviral therapy (HAART). In a similar way, cancer drugs will be used in 
parallel or sequentially to block different driver pathways and networks simultaneously. 
Although there are a number of mechanisms of resistance that are particular to molecularly 
targeted agents and are intrinsic to the pathway they inhibit, there are other mechanisms 
that are common to both cytotoxic chemotherapy and molecularly targeted agents falling 
into three main categories: decreased uptake, such as occurs with water-soluble drugs like 
the folate antagonists; impaired capacity of cytoxic drugs to induce cell kill via a 
combination of altered cell cycle checkpoints, increased or altered drug targets, repair of 
DNA damage and inhibition of apoptosis; or increased drug efflux (Gottesman et al., 2002; 
Szakacs et al., 2006). 
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The presence of efflux pumps is one of the best described mechanisms of resistance and is 
thought to be common to both cytotoxic chemotherapy and the molecularly targeted agents. 
P-glycoprotein (P-gp), otherwise known as the multidrug transporter, is an energy 
dependent efflux pump that has been identified as a major mechanism of multidrug 
resistance (MDR) in cultured cancer cells. It is the product of the MDR1 gene in humans and 
is one member of a large family of ATP-dependent transporters known as the ATP-binding 
cassette (ABC family). P-gp is widely expressed in many human cancers including cancers 
of the gastrointestinal tract, hematopoietic system, genitourinary system and childhood 
cancers. P-gp can detect and bind a large variety of hydrophobic natural-product drugs as 
they enter the plasma membrane including chemotherapeutic agents such as doxorubicin, 
vinblastine and paclitaxel, as well as anti-arrhythmics, antihistamines and the HIV protease 
inhibitors (Robert., 1999). Increased drug efflux was initially thought to be a significant 
mechanism of resistance for the tyrosine kinase inhibitor imatinib in patients with CML 
(Mahon et al., 2003). However, it is not fully understood how much impact this resistance 
mechanism has on molecularly targeted drugs as a prime source of resistance. 
Another relevant mechanism of resistance that has been illustrated in a number of cancers 
involves the disruption of interacting proteins and receptors on the plasma membrane level 
impacting on receptor binding and subsequent drug efficacy. For example, EGFR is a 
membrane-bound receptor whose signalling involves a complex pathway of ligand binding, 
receptor homo- and heterodimerisation with ERBB2 and other family members, followed by 
internalisation and recycling of the ligand-bound receptor. Significant EGF-dependent 
signalling may occur during the process of internalisation and alterations in EGFR 
trafficking have been linked to cellular responses (Wiley et al., 2003). Analysis of EGFR 
trafficking in resistant lung cancer cell lines demonstrated increased internalisation of EGFR 
compared to parental drug-sensitive cells, which interestingly could be overcome by the 
action of irreversible EGFR inhibitors (Kwak et al., 2005). Similarly in breast cancer, one of 
the proposed mechanisms of resistance to trastuzumab involves membrane-associated 
glycoprotein mucin-4 (MUC4) which may block the inhibitory actions of trastuzumab by 
directly binding with HER2 and preventing interaction between the drug and the molecular 
target (Nagy et al., 2005). 
Primary or secondary mutations and aberrations at the level, up- or downstream of the 
target are also frequently studied mechanisms of resistance to the molecularly targeted 
agents. For example, primary resistance to the EGFR targeted agents, gefitinib and erlotinib, 
has been associated with the presence of a KRAS mutation in 20-30% of NSCLC patients, or 
via an insertion mutation in exon 20 of EGFR, which represents fewer than 5% of all known 
mutations in the EGFR gene (Hammerman et al., 2009). Secondary resistance to the EGFR 
inhibitors after an initial response is mediated by the T790M mutation in 50-59% of patients, 
characterised by the substitution of methionine for threonine at position 790 (T790M) in 
EGFR (Pao et al., 2005). In this case, biological understanding of primary and secondary 
resistance allows for development of rationally designed drugs. Pre-clinical evidence 
demonstrated that an irreversible inhibitor of EGFR, such as neratinib (HKI-272), could 
overcome resistance induced by T790M-mutant EGFR and such agents are currently in 
clinical development (Kobayashi et al., 2005; Kwak et al., 2005). 
Recent advances in the treatment of melanoma have further assisted in the understanding of 
the complexity of resistance mechanisms. For example although secondary BRAF mutations 
have not been identified as a cause of BRAF inhibitor resistance, mutations elsewhere along 
the MAPK pathway have been implicated, including secondary NRAS and MEK mutations. 
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MEK mutations have been demonstrated to cause reactivation of ERK signalling despite 
BRAF or MEK inhibition both in vitro and in vivo (Corcoran et al., 2011; Emery et al., 2009; 
Wagle et al., 2011). Similarly NRAS mutations, such as the NRAS Q61K mutation, have been 
demonstrated in BRAF mutant melanoma cell lines resistant to vemurafenib, and in a nodal 
biopsy from a patient who progressed after an initial response on treatment (Nazarian et al., 
2010). The presence of an NRAS mutation can result in persistently elevated pMEK and 
pERK levels despite BRAF inhibition and is thought to signal through RAS and 
subsequently through RAF isoforms other then BRAF (Nazarian et al., 2010).  
Signalling via the CRAF isoform is also a significant mechanism of resistance, with increased 
CRAF activity and a switch from BRAF to CRAF dependency demonstrated in BRAF mutant 
melanoma cell lines that are resistant to RAF inhibition (Montagut et al., 2008). Importantly, 
sensitivity to MEK inhibition was maintained in these cell lines, supporting further novel drug 
combinations, such as a non-selective RAF inhibitor or selective CRAF inhibitor with a MEK or 
BRAF inhibitor to overcome this mechanism of resistance.  
Amplification of the mutant BRAF allele has also been implicated in resistance via increased 
pMEK and subsequently pERK signalling, though the evidence for this lies in studies of 
BRAF mutant colorectal cancer cell lines. In three such cell lines, BRAF amplification was 
demonstrated as a mechanism of acquired resistance to MEK inhibitors with cross-resistance 
to BRAF inhibitors, although to a lesser degree (Corcoran et al., 2010; Little et al., 2011). 
Preclinical studies showed that increased concentrations of RAF or MEK inhibitors, as well 
as the combination of the two agents, could suppress ERK phosphorylation and 
downstream signalling (Corcoran et al., 2010). 
Changes in signalling upstream of a target pathway as well as bypass signalling along 
alternate pathways have also been demonstrated as mechanisms of resistance (Figure 3). In 
this context the insulin-like growth factor 1 receptor (IGF1R) which signals upstream of the 
PI3K-AKT-mTOR and MAPK pathways has been found to contribute to resistance in a 
number of malignancies. For example, activity of trastuzumab was impaired in breast cancer 
cells that over-expressed both HER2 and IGF1R, but its activity could be restored when 
IGF1R activation was blocked (Lu et al., 2001). Moreover, in vitro models have 
demonstrated that IGF1R physically interacts with and induces phosphorylation of HER2 in 
trastuzumab-resistant cells, but not in trastuzumab-sensitive cells, with subsequent 
increased signalling through the PI3K-AKT-mTOR and MAPK pathways. Again, inhibition 
of IGF1R signalling either by antibody blockade or tyrosine kinase inhibition restored 
trastuzumab sensitivity, demonstrating another potential therapeutic mechanism to 
overcome secondary resistance to trastuzumab. Similar findings were also evident in BRAF 
V600E melanoma cell lines resistant to BRAF inhibition, providing early evidence for the 
combination of IGF1R and MEK inhibition in this setting. (Villanueva et al., 2010). 
A number of other preclinical studies have also demonstrated aberrant activation of the PI3K-
AKT pathway at other levels that contributes to both primary and secondary resistance in 
BRAF mutant cell lines (Jiang et al., 2011; Shao et al., 2010). Just as the combination of IGF1R 
inhibition with MEK inhibition is being investigated to overcome resistance mediated along 
the IGF1R and MAPK pathways, there may be a biologic rationale for the combination of PI3K 
and MEK inhibitors (Jiang et al., 2010). In such cases, phosphorylated AKT may act as a 
marker of activity of the PI3K-AKT-mTOR pathway and thus, may be used as a biomarker to 
select when the combination of PI3K inhibitors and BRAF/MEK inhibitors is appropriate to 
block both the PI3K and MAPK pathways respectively.  
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PTEN loss (PTEN-) and subsequent lack of inhibition on the PI3K-AKT-mTOR pathway has 
also been demonstrated to confer resistance to BRAF inhibition. Paraiso et al. (2011) showed 
that in cell lines with PTEN loss compared to cell lines with normal PTEN, BRAF inhibition 
with vemurafenib was associated with increased AKT signalling and decreased apoptosis. 
Dual treatment of PTEN- cell lines with both vemurafenib and a PI3K inhibitor could then 
restore increased levels of apoptosis (Paraiso et al., 2011). 
Exemplified by preclinical and clinical examples in melanoma, signalling via the PI3K-AKT-
mTOR pathway mediates an important MAPK-pathway independent mechanism of 
resistance in a variety of cancers and demonstrates a complex crosstalk between these 
pathways (Corcoran et al., 2011). Measurement of phosphorylated ERK and phosphorylated 
AKT to determine pathway activity may therefore help to guide therapeutic choices and 
combinations of selective BRAF, MEK or PI3K/AKT inhibitors. Thus, knowledge of 
secondary resistance mechanisms will increasingly influence decision making processes for 
further drug development and rational drug combinations. 
Although mechanisms of secondary resistance are well described for several new targeted 
agents, challenges remain, particularly with anti-angiogenic or multitargeted agents such as 
bevacizumub, sunitinib and sorafenib. The complexity of resistance mechanisms to anti-
angiogenic therapy reflects the difficulty in developing anti-angiogenic agents in parallel 
with corresponding biomarkers.  
So far, two main resistance mechanisms for anti-angiogenic agents have been proposed: 
firstly, evasive resistance with adaptation to circumvent specific angiogenic blockade, and 
secondly, intrinsic or pre-existing indifference (Bergers & Hanahan., 2008). Evasion of anti-
angiogenic therapy may occur via up-regulation of alternative pro-angiogenic signalling 
circuits or via a number of alterations in the micro-environment, including recruitment of 
vascular progenitor cells and pro-angiogenic monocytes from the bone marrow, increased 
and tight pericyte coverage protecting tumour blood vessels and increased capacity for 
invasion without angiogenesis.  
Alternate pro-angiogenic signals that have been implicated in preclinical studies include 
fibroblast growth factor (FGF)-1 and -2, ephrin A1 and A2 and angiopoietin-1. To establish 
the significance of these up-regulated genes, preclinical studies used the combination of FGF 
signalling suppression with VEGFR inhibitors and demonstrated that the combination of 
these agents attenuated re-vascularisation and slowed tumour growth (Casanovas et al., 
2005). These findings were also seen clinically in patients with glioblastoma treated with the 
VEGFR inhibitor cediranib (Batchelor et al., 2007). After initial response, peripheral blood 
levels of FGF2 increased when patients progressed, suggesting that signalling through FGF 
assists in restoring angiogenesis. Elevated levels of pro-angiogenic factors such as VEGF and 
placental growth factor (PGF) have been previously proposed as predictive biomarkers for 
tumour response (Bocci et al., 2004). However there is also evidence that the expression of 
pro-angiogenic growth factors such as FGF, PDGF and others increase in advanced stages of 
metastatic breast cancer, resulting in alternate pathway signalling (Relf et al., 1997). Thus, 
there is uncertainty regarding the significance of these factors; whether the presence of pro-
angiogenic factors in peripheral blood are in fact markers of response or resistance, or 
neither. Understanding the complex regulatory networks, the interaction of pro- and anti-
angiogenic factors and contributing components of the micro-environment, illustrates the 
difficulties to-date in target and biomarker development, as well as the potential 
mechanisms by which anti-angiogenic therapy can be optimised. 
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Malignancy and 
Drug 
Target Biomarker Mechanisms of Resistance 
Under investigation 
Breast cancer    
Tamoxifen Estrogen 
receptor 
ER/PR status on IHC Loss of ER expression 
Epigenetic changes in ER gene 
Increased drug metabolism 
ER/HER2 cross-talk 
PI3K-AKT pathway activation 
Alterations in co-regulatory 
proteins 
(Ring et al., 2004) 
Trastuzumab HER2 receptor HER2 expression on 
IHC and/or FISH 
MUC4 binding to HER2  
(Nagy et al.; 2005) 
HER2 & IGF1R crosstalk  
(Lu et al., 2001) 
PI3K-AKT pathway signalling 
and PTEN loss 
Bevacizumab* VEGF-A and 
VEGFR2 
Nil currently 
validated 
 
Preliminary evidence 
on clinical, 
biochemical and 
radiological 
assessments 
Alternate pro-angiogenic 
signalling circuits (eg. FGF) 
Bone marrow derived vascular 
progenitor cells & pro-angiogenic 
monocytes 
Increased pericyte coverage 
(Bergers & Hanahan, 2008) 
Melanoma    
Sorafenib RAF, VEGFR, 
PDGFRβ, 
cKIT, FLT3 
Nil currently 
validated 
Alternate pro-angiogenic 
signalling, PDGFR mt 
Glucose-regulated protein 78  
(Chiou et al., 2010) 
Vemurafenib/ 
GSK 2118436 
BRAF 
V600E/K mt 
BRAF mt status Upstream: IGF1R, PDGF 
upregulation, NRAS mt (Nazarian 
et al., 2010; Villanueva et al., 
2010)) 
Target level: BRAF amplification, 
CRAF activity (Corcoran et al., 
2011; Montagut et al., 2008) 
Downstream: MEK mt (Corcoran 
et al., 2011) 
Alternate pathway signalling: 
PI3K-AKT-mTOR activation 
Lung Cancer    
Erlotinib/ 
Gefitinib 
EGFR EGFR mt status KRAS mt 
EGFR T790M mt 
(Pao et al., 2005) 
EGFR insertion mt in exon 20 
(Hammerman et al., 2009)  
EGFR trafficking (Kwak et al., 
2005) 
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Malignancy and 
Drug 
Target Biomarker Mechanisms of Resistance 
Under investigation 
Crizotinib ALK and MET 
tyrosine 
kinases 
EML4-ALK 
expression on IHC, 
ISH and/or RT PCR 
EML4-ALK with C1156Y mt 
EML4-ALK with L1196M mt 
(Choi et al., 2010) 
Colorectal 
Cancer 
   
Cetuximab EGFR KRAS mt  
(codon 12) 
KRAS codon 61/146 mt  
BRAF mt (Loupakis et al., 2009) 
PIK3CA mt  
(Sartore-Bianchi et al., 2009) 
PTEN loss of expression  
(Frattini et al., 2007) 
Haematologic 
malignancies 
   
Imatinib 
 
 
BCR-ABL 
tyrosine 
kinase, cKIT 
BCR-ABL mRNA on 
PCR (peripheral 
blood) 
Cytogenetic analysis 
on bone marrow 
aspirate 
Drug efflux (Mahon et al., 2003) 
ATP binding site mt  
(Branford et al., 2003) 
 
KIT mutation (in GIST) 
(Tamborini et al.; 2004) 
CAL-101 PI3K p110δ pAkt and markers 
along the PI3K δ 
pathway 
 
*Evidence for bevacizumab also applies to colorectal cancer, NSCLC, renal cell carcinoma and other 
malignancies 
ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor 2; 
IHC: immunohistochemistry; mt: mutation 
IGF1R: insulin growth factor-1 receptor; PDGF: platelet derived growth factor 
EGFR: epidermal growth factor receptor; PI3K: phosphatidylinositol-3kinase 
PTEN: phosphatise and tensin homologue 
Fig. 3. Selected Examples of Molecularly Targeted Therapies and Mechanisms of Drug 
Resistance 
5.2 The breakthroughs and dilemmas of recurrent tumour biopsies 
Although many mechanisms of resistance can be identified through studies of cell lines and 
xenograft models, it is often through correlation with patients’ tumour specimens that valid 
conclusions can be drawn about the significance of these resistance mechanisms in the 
clinical setting. To this end, access to longitudinal tumour biopsies and assessment of these 
in ‘real-time’ may change the treatment paradigm for patients. 
The need for longitudinal tumour biopsies is evidenced at a number of levels. Firstly, it 
assists in understanding and mapping the complex molecular networks, communication 
with the micro-environment, angiogenesis and other ‘hallmarks’. As technologies in tumour 
analysis improve, for example with high throughput genetic sequencing and unravelling the 
cancer genome, findings on the pre-clinical level can be investigated and explored clinically 
and changes in tissue can be correlated with therapeutic response.  
Secondly, there are multiple variables that can affect the accuracy of mutational analysis on 
tumour tissue, not least that the tumour itself can develop new mutations and aberrations 
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that drive tumorigenesis. Studies of concordance or lack thereof, between archival primary 
tissue and biopsies of metastatic disease have demonstrated this in breast, colorectal and 
other malignancies. Analyses of HER2 over-expression in primary breast cancer and 
metastatic sites demonstrate that up to 12% of patients may have HER2 negative primary 
breast cancers with HER2 positivity at the metastatic sites, and subsequent potential 
therapeutic benefit from trastuzumab (Zidan et al., 2005). Conversely, up to 30% of tumours 
could switch from HER2 positive status on primary tissue to HER2 negative status on 
metastatic tissue, again significantly impacting on future treatment decisions (Locatelli et al., 
2010). 
In patients with advanced colorectal cancer, retrospective analyses have assessed the 
concordance of KRAS mutation status and other alterations along the MAPK and PI3K-
AKT-mTOR pathways between primary tumours and metastatic sites. Loupakis et al. (2008) 
assessed PTEN status which regulates the PI3K-AKT-mTOR pathway, and demonstrated 
that PTEN loss occurred in 37% of tumours with associated lack of response to cetuximab 
and irinotecan. Interestingly the reported PTEN concordance between primary tumours and 
metastases was 60% compared to 95% for KRAS mutations. In those patients who were 
KRAS wild-type and PTEN positive on metastases, there was evidence for improved RR and 
PFS indicating the importance of pathway profiling to predict clinical response. 
These examples underline the importance of tumour assessment not only for patients who 
develop metastatic disease after resection of a primary cancer, but also for patients with 
progressive disease on treatment. Understanding of the ‘driving’ pathway, receptor or 
network before treatment initiation, especially with new molecularly targeted agents, will 
become standard of care for several new treatments and guide us in the decision making 
algorithm even in advanced stages of disease.  
This can be further evidenced by a recent study in a cohort of heavily pre-treated phase-I 
patients who were tested for aberrations in the MAPK and PI3K-AKT-mTOR pathways and 
then treated with drugs targeting these pathways (Tsimberidou et al., 2011). Impressively, 
those patients with molecular alterations treated with targeted therapy had a response rate 
of 29% (complete response or partial response) compared to 8% in the group without 
alterations. The proportion of patients with stable disease beyond 6 months and the median 
survival were also higher in this patient group. 
Importantly the recent early phase-I melanoma studies with selective BRAF inhibitors have 
incorporated tumour biopsies at baseline, on-treatment and on-progression biopsies to 
analyse the changes in pathway signalling (McArthur et al., 2011; Nathanson et al., 2011). 
The tumour analyses included not only immunohistochemical staining, but also Sequenom 
MassARRAY of over 400 gene mutations, such as BRAF, RAS, PIK3CA, AKT1/2, CDK4 and 
others. Following this approach, patients were selected for the BRAF mutation at baseline 
and monitored during treatment with the measurement of phosphorylated MEK and ERK 
levels to confirm target inhibition. On progression, a number of potentially significant 
genetic alterations were identified, including NRAS and MEK1 mutations indicating 
continuing MAPK-pathway signalling. In addition PTEN loss and an increase in pAKT were 
observed, demonstrating activation of the PI3K-AKT-mTOR pathway as a possible alternate 
signalling pathway (Figure 2).  
Clearly the risk-benefit of serial tumour biopsies needs to be well balanced and risks and 
disadvantages acknowledged. For example, in some cancers like NSCLC, access to tumour 
tissue is restricted by the site of disease with an increased potential risk of pneumothorax, 
www.intechopen.com
 
Drug Discovery and Development – Present and Future 58
bleeding and other complications secondary to a lung biopsy. Tissue biopsies also run the 
risk of sampling error, in part from tumour heterogeneity. As discussed with HER2 testing 
in gastric cancer, multiple biopsies may be required to minimise the chance of missing the 
alteration of interest, in this case HER2 amplification and protein over-expression. In 
addition sample handling, fixation, validation of assays, inter-observer variability and 
assessment, all contribute to the accuracy of the final result on which clinical decisions are 
made.   
Finally, new technologies also need to be validated prior to routine introduction into clinical 
care. Although the ability to sequence the genome and perform genetic profiling on patients’ 
tumours dramatically escalates the information available on an individual patient, the 
significance of this information is still, as yet, often unknown. The presence of a mutation 
does not determine its significance in tumorigenesis, such that inhibition of a given 
mutation will not correlate with clinical benefit, if the mutation was an incidental finding 
rather than an oncogenic mutation. 
5.3 The role of circulating tumour cells and circulating free DNA 
Detection of circulating tumour cells (CTCs), and circulating free DNA (cfDNA) in 
peripheral blood specimens potentially presents an easily accessible ‘liquid biopsy’ without 
the risk of tumour biopsies and further, may not only provide a predictive biomarker for a 
given treatment, but also contain information on molecular aberrations and changes in 
pathway signalling while on treatment.  
There is increasing evidence that CTCs can be used as a surrogate endpoint for progression-
free and overall survival and thus, allow an earlier assessment of the clinical benefit of a 
particular agent to streamline drug development and regulatory approval. Such ‘surrogate 
endpoints’ may accelerate drug development as long as adequate and well controlled 
clinical trials establish that the new drug has an effect on this surrogate, based on 
epidemiologic, therapeutic, pathophysiologic, or other evidence, and that this surrogate 
endpoint can predict clinical benefit and survival (Atkinson et al., 2001). 
The enumeration of CTCs and their utility as a prognostic and predictive biomarker has 
been best characterised in breast, colorectal and prostate cancers with further evidence in 
other malignancies including melanoma and lung cancers. The most widely used and FDA 
approved method for CTC enumeration and molecular characterisation is the CellSearch 
system, which involves the immunomagnetic capture of CTCs using antibodies against the 
epithelial cell adhesion molecule (EpCAM), expressed on the cell surface of most epithelial 
malignancies. Additional cell identification includes the detection of pan-cytokeratin 
antibodies, DAPI nuclear staining (4,6-diamidino-2-phenylindole staining to detect 
nucleated cells) and CD45 negative selection to demonstrate the detected cell is not a 
leucocyte.  
The presence of CTCs at baseline in metastatic breast cancer has not only been demonstrated 
to have prognostic significance but has also been shown to be the strongest predictor of 
overall survival when compared to age, hormone receptor status, HER2 status and 
metastatic site. It also maintains its prognostic value independent of line of treatment, site of 
recurrence and disease phenotype (Cristofanilli et al., 2005). Preliminary studies in breast 
cancer suggest that CTC enumeration may even be superior to radiological evaluation in 
predicting response to treatment and outcome. It may provide a more reproducible indication 
of disease status compared to current imaging methods, particularly in view of inter-reader 
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variability in confirming radiological response which can vary by up to 15% compared to 1% 
variability for CTC counts (Budd et al., 2006).  
In castrate resistant prostate cancer, the presence of CTCs at baseline and lack of a decline 
during treatment is also indicative of poor response and survival. In multivariate analyses, 
CTC counts and PSA doubling time have been demonstrated as the only independent 
predictors for clinical outcome as compared to PSA level, Gleason Score, bone metastases 
and age (De Bono et al., 2008). Additionally, there is now evidence that CTCs may be a 
potential surrogate biomaker in metastatic prostate cancer trials. The randomised, double-
blind phase III trial in metastatic prostate cancer, in which abiraterone was compared to 
placebo, was the first of its kind to demonstrate the utility of CTCs in this setting. CTCs 
were measured at baseline and repeated at 4, 8 and 12 weeks post treatment. Pre-treatment 
CTCs were strongly correlated with OS, as was a fall in CTC count on treatment (Reid et al., 
2010; Scher et al., 2011). Particularly in the setting of castrate resistant prostate cancer where 
there may be inter-observer variation regarding radiological progression, CTCs may 
provide an accurate and reproducible alternative. 
In patients with metastatic colorectal cancer, higher baseline CTC counts correlate with 
shorter PFS and OS. Again, conversion of an unfavourable baseline CTC count to a 
favourable count at 3-5 weeks after starting treatment is associated with longer PFS and OS 
compared with patients with unfavourable counts at both time points. Baseline and follow-
up CTC levels also remain strong predictors of PFS and OS after adjustment for clinically 
significant factors (Cohen et al., 2008).  
Recent evaluation of CTCs in patients with NSCLC has also suggested prognostic 
significance (Krebs et al., 2011). CTCs in patients with NSCLC were found more commonly 
with stage IV (32%) compared to stage IIIB disease (7%) and in those patients with five or 
more CTCs detected, both PFS and OS were inferior. Particularly with the complexities in 
obtaining longitudinal tissue biopsies, further investigation of a prognostic ‘liquid biopsy’ 
and incorporation into early phase trials is of importance. 
In patients with advanced melanoma, recent studies have demonstrated good correlation 
between CTC status and tumor-node-metastasis stage, underlining the prognostic role of 
CTCs (Mocellin et al., 2006). The predictive value of CTCs was so far limited by the fact that 
treatment options consisted of bio-chemotherapies with no effects on clinical outcomes. 
However, the presence of circulating melanoma cells after adjuvant treatment for stage III 
melanoma has been shown to correlate with inferior relapse-free and overall survival and 
may be a useful indicator of systemic subclinical disease (Koyanagi et al., 2005). Isolation 
and molecular characterisation of these cells, combined with analysis of cfDNA, presents an 
opportunity to obtain further information about the pathways driving tumorigenesis, 
invasion and metastasis. In addition to evaluating the role of CTCs in melanoma, one study 
found good correlation between CTCs and cfDNA suggesting both markers may be a useful 
determinant of disease status and treatment effect. Patients with measurable CTC or cfDNA 
showed poorer disease outcome compared with patients without these markers, and 
patients with both markers showed the most inferior disease outcome, despite the fact that 
the treatment regimens were heterogenous and consisted of bio-chemotherapies of limited 
clinical benefit (Koyanagi et al., 2006). 
5.4 Optimising trial design 
Given the diversity of novel compounds discovered over the last decade, clinical trial design 
for the evaluation of these targeted agents has evolved with the agents being tested. Many 
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of these agents do not cause typical chemotherapy-induced side effects such as 
myelosupression around which early phase trial design has been based. Therefore design of 
clinical trials of novel agents has had to develop in order to evaluate these agents 
appropriately and efficiently.  
In a standard dose escalation phase I trial, cohorts of three to six patients are treated at pre-
defined dose levels, dose-limiting toxicity (DLT) is observed and the maximum tolerated 
dose (MTD) is defined as the dose level where >33% of patients treated have experienced a 
DLT. Dose levels are commonly defined using modification of the original Fibonacci design 
(increasing dose by fixed increments of 100%, 67%, 50%, 40% followed by 33% for all 
subsequent levels) but slow attainment of the MTD and exposure of significant numbers of 
patients to low doses have been criticisms of this approach (Rogatko et al, 2007). An 
accelerated trial design (Simon et al, 1997) is now a widely accepted alternative to the 
Fibonacci dose-definition model and many trials now allow individual patients to be dose-
escalated within a study if safe to do so, aiming to minimise those being exposed to 
ineffective doses. Therefore there are many combinations of model-based and rule-based 
designs that allow flexibility of the recruitment structure in a trial and can be appropriately 
adapted to the agent under consideration (Ivy et al., 2010; Parulekar et al., 2004; Rogatko et 
al, 2005; Korn et al, 2001; Cannistra et al., 2008; Sleijfer et al., 2008; Bria et al., 2009). 
The appropriateness of the primary endpoint of maximum tolerated dose (MTD) has been 
challenged for some of these agents and consideration has been given instead to the concept 
of optimal biological dose (OBD) (O’Reilly et al., 2010; Le Tourneau et al., 2009). Targeted 
biological agents are more commonly cystostatic rather than cytotoxic, therefore other 
endpoints should be considered when evaluating treatment efficacy (Rixe et al., 2007; 
Gelmon et al., 1999) including novel radiographic assessment and immunotherapy 
assessment (Wolchok et al., 2009).  
There has also been an increasing realization that patients need to be appropriately selected 
for certain agents based on tumour biology and molecular characteristics. The question is 
whether patient selection should take place at the outset of drug development, as a targeted 
approach which is then diversified; or whether a broader recruitment strategy should 
prevail initially, followed by testing within a targeted population. There is therefore a 
critical need to integrate and validate novel biomarkers into drug development from the 
earliest stages of evaluation, incorporating tumour and non-tumour tissue samples to apply 
these biomarkers appropriately and guide patient selection. 
Overall, in the era of development of molecularly targeted agents, appropriately designed 
hypothesis-testing trials should be conducted. Patients should be selected rationally 
according to tumour biology and molecular characteristics and above all, an element of 
flexibility should be allowed within the trial design to enable response to unexpected 
findings, whether that be toxicity or efficacy. 
6. Conclusion 
The increased understanding of tumour biology and genetics along with improvements in 
laboratory methodologies and IT-systems will continue to make a tremendous impact on 
oncology drug development. Critical to future oncology drug development is the 
incorporation of biomarkers from the earliest stages and supported by applied 
bioinformatics. In addition, the use of new preclinical models and novel clinical trial designs 
incorporating intermediate surrogate biomarker endpoints will be essential not only for the 
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better understanding of mechanisms of action of new targeted drugs, but also in supporting 
confident ‘go or no-go decisions’. The ‘personalised medicine’ approach involving molecular 
characterisation of the tumour and its context within the micro-environment and immune 
system, will help to define the right treatment, for the right patient at the right time. 
Increasing our understanding on how to combine established and novel therapeutics in an 
efficient timeframe is critical to improved outcomes for the treatment of solid malignancies.  
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